Orforglipron vs Tesamorelin
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Orforglipron
Orforglipron (LY3502970) is a non-peptide, oral GLP-1 receptor agonist developed by Eli Lilly. Unlike oral semaglutide (which is a peptide requiring special formulation), orforglipron is a small molecule — the first of a new class of oral GLP-1 drugs that can be taken without fasting restrictions. It is in Phase 3 trials for obesity and type 2 diabetes, with an FDA decision expected in 2026. Projected to reach $16 billion in annual sales by 2031.
Full details →Tesamorelin
Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH). It is FDA-approved under the brand name Egrifta for reducing excess abdominal fat in HIV-infected patients with lipodystrophy.
Full details →Side-by-Side Comparison
| Aspect | Orforglipron | Tesamorelin |
|---|---|---|
| Mechanism | Orforglipron is a small-molecule agonist that binds and activates the GLP-1 receptor through the same signaling cascade as peptide GLP-1 agonists (cAMP elevation, insulin secretion, appetite suppression) but with a fundamentally different molecular structure. Being a non-peptide, it does not require protection from enzymatic degradation (no fatty acid conjugation needed), can be absorbed without special formulation, and has no fasting restrictions for administration. Once-daily oral dosing with a half-life of ~25-65 hours. | Stimulates the pituitary gland to produce and release growth hormone by binding to GHRH receptors. Increases IGF-1 levels which promotes lipolysis and reduces visceral adipose tissue. |
| Typical Dosage | Phase 2 trial doses: 12 mg, 24 mg, 36 mg, and 45 mg daily. The 36 mg and 45 mg doses showed greatest efficacy. Phase 3 trials are evaluating doses of 12-60 mg daily. No fasting requirement — can be taken with or without food at any time of day. Final approved dosing not yet established. | FDA-approved dose: 2mg administered subcutaneously once daily. Research protocols may use various dosing schedules. |
| Administration | Oral tablet, once daily. No fasting restrictions required (a major advantage over oral semaglutide). Phase 3 trials ongoing. Expected FDA decision in 2026. Not yet commercially available. | Subcutaneous injection into the abdomen. Rotate injection sites. Best administered at the same time daily, preferably in the evening. |
| Side Effects | Phase 2 data: nausea (up to 35%), vomiting (up to 19%), diarrhea (up to 18%), constipation, decreased appetite. GI side effects were dose-dependent and generally transient, decreasing with continued use. Discontinuation rates due to GI events were 6-12%. | Common side effects include injection site reactions (erythema, pruritus), joint pain, peripheral edema, and muscle pain. May cause elevated blood glucose. |
| Best For |
Key Differences
Unique to Orforglipron:
Unique to Tesamorelin:
Detailed Analysis
Commonalities
Orforglipron and Tesamorelin are used for different purposes and have limited overlap in their applications.
Which Should You Choose?
Choose Orforglipron for Weight Loss, Diabetes Management. Choose Tesamorelin for Muscle Growth, Fat Loss.
Ready to Learn More?
Looking for trusted sources?